Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Table 1 Summary of Roche-sponsored lead-in H trials for the ROP Study

Lead-in protocol ID number	Study design	Patient population	Total patients in lead-in study, N	Patients included in ROP Study, n (%)
BO16216	Anastrozole ± H	Breast cancer	208	4 (16.0)
BO18255	H + cisplatin + FU or X	Gastric cancer	594	6 (24.0)
H0648g	H + AC or pac	Breast cancer	469	1 (4.0)
H0649g	H monotherapy	Breast cancer	222	1 (4.0)
M77001	H + T	Breast cancer	188	2 (8.0)
M77003	H + EC	Breast cancer	120	6 (24.0)
MO16419	H + T + X	Breast cancer	225	3 (12.0)
WO16229	H monotherapy	Breast cancer	105	1 (4.0)
WO17229	H + T or pac	Breast cancer	46	1 (4.0)

Abbreviations: A anthracycline, C cyclophosphamide, E epirubicin, H trastuzumab (Herceptin®), FU fluorouracil, pac paclitaxel, ROP Rollover Protocol, T docetaxel, X capecitabine

ISSN: 1471-2407